Skip to main content
Log in

MSI und Tumormutationslast beim kolorektalen Karzinom

MSI and tumor mutational burden in colorectal cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Venook AP, Niedzwiecki D, Lenz H et al (2017) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317(23):2392–2401. https://doi.org/10.1001/jama.2017.7105

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fabian Kütting.

Ethics declarations

Interessenkonflikt

F. Kütting, M. Bludau, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kütting, F., Bludau, M., Alakus, H. et al. MSI und Tumormutationslast beim kolorektalen Karzinom. Onkologe 25, 829–830 (2019). https://doi.org/10.1007/s00761-019-0611-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-019-0611-4

Navigation